|Last Price||Today's Change||52-Week Range||Trading Volume|
|59.94||-1.11 (-1.82%)||47.36 - 68.75||4.1 million (Above Avg)|
Market data as of 4:02PM 05/26/15. Quotes are delayed by at least 15 min.
Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congress (IHC): Efficacy and Safety Results at All Doses and Endpoints Present Robust Case for Progression to Phase III
05/14/2015 8:30 AM ET